Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
WW domain-containing transcription regulator 1 (TAZ) is a transcriptional coactivator and downstream regulatory target within the Hippo signaling pathway, crucial for controlling organ size and suppressing tumors by restricting cell proliferation and promoting apoptosis. It is structurally related to Yes-associated protein (YAP) and contains both a WW domain for interaction with PPXY motifs in transcription factors and a C-terminal PDZ-binding motif, which enables subcellular localization and function. TAZ activity is negatively regulated by 14-3-3 protein-mediated nuclear export and positively regulated via PDZ domain interactions. It modulates the transcriptional activity of multiple factors and has important roles in stem cell self-renewal, cell proliferation, epithelial-mesenchymal transition, and differentiation, with its dysregulation implicated in cancer development and progression[1][3][4][5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on WW domain-containing transcription regulator 1 (TAZ).